Colon Pharmaceutical announced on May 8 that its subsidiary Sichuan Colun Botai Biomedical Co., Ltd. (“Colun Botai”) plans to issue H shares at the same time as issuing H shares on the Hong Kong Stock Exchange (see relevant information disclosed on the Hong Kong Stock Exchange's website for details). The company plans to subscribe for all of its targeted domestic shares. The two parties signed the “Targeted Issuance of Shares Subscription Agreement” on May 8, 2024. The subscription price is determined according to the price of H shares issued by Columbaix on the Hong Kong Stock Exchange after considering exchange rate factors. The subscription amount is RMB 136.21 per share. The subscription amount is 4,423,87 million shares, and the subscription amount is 603 million yuan. After the subscription is completed, the company and its wholly-owned subsidiary Colun International Development Co., Ltd. will directly hold about 54.80% of Columbite's shares, and the company will remain the controlling shareholder of Columbite.
科伦药业：拟6.03亿元认购子公司科伦博泰在港交所发行的442万股内资股股份
Colon Pharmaceutical: Plans to subscribe for 4.42 million yuan of the 4.42 million domestic shares issued by the subsidiary Colunbotai on the Hong Kong Stock Exchange
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.